1.Are Clinically Insignificant Prostate Cancers Really Insignificant among Korean Men?.
Chan Dong YEOM ; Seung Hwan LEE ; Kyung Kgi PARK ; Sang Un PARK ; Byung Ha CHUNG
Yonsei Medical Journal 2012;53(2):358-362
PURPOSE: We aimed to determine whether 12 core-extended biopsies of the prostate could predict insignificant prostate cancer (IPCa) in Koreans reliably enough to recommend active surveillance. MATERIALS AND METHODS: Two hundred and ninety-seven patients who underwent radical prostatectomy after 12 core-extended prostate biopsies were retrospectively reviewed. 38 cases (12.8%) were shown to be IPCa. RESULTS: The average age was 65.2 years, serum PSA was 5.49 ng/dL, and the PSA density was 0.11. The Gleason scores (GS) were 6 (3+3) in 31, 5 (3+2) in 4, and 4 (2+2) in 3. After radical prostatectomy, higher GS was given in 16 (42.1%), whereas lower GS was given in 1 case (2.6%), as compared with the GS obtained from biopsy. 11 (28.9%) had GS of 7 (3+4) and 5 (13.2%) had GS of 7 (4+3). 6 in GS 7 (4+3) and 1 in GS 7 (3+4) showed prostate capsule invasion and 1 in GS 7 (4+3) had seminal vesicle invasion. Prostate capsule invasion was observed in 1 with GS 6 (3+3). The rate of inaccuracy of the contemporary Epstein criteria was 42.1%. Only PSA density was a reliable indicator of clinically IPCa (odds ratio=1.384, 95% CI, 1.103 to 2.091). CONCLUSION: Diagnosis of IPCa from a prostate biopsy underestimated the true nature of prostate cancer in as many as 42.1% of Koreans.
Aged
;
Humans
;
Male
;
Middle Aged
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/blood/*diagnosis/surgery
;
Retrospective Studies
2.Clinical Use of -2proPSA (p2PSA) and Its Derivatives (%p2PSA and Prostate Health Index) for the Detection of Prostate Cancer: A Review of the Literature.
Alberto ABRATE ; Giovanni LUGHEZZANI ; Giulio Maria GADDA ; Giuliana LISTA ; Ella KINZIKEEVA ; Nicola FOSSATI ; Alessandro LARCHER ; Paolo DELL'OGLIO ; Francesco MISTRETTA ; Nicolomaria BUFFI ; Giorgio GUAZZONI ; Massimo LAZZERI
Korean Journal of Urology 2014;55(7):436-445
Prostate-specific antigen (PSA) is recognized as an organ-specific marker with low specificity and sensitivity in discriminating prostate cancer (PCa) from other benign conditions, such as prostatic hyperplasia or chronic prostatitis. Thus, in the case of clinical suspicion, a PCa diagnosis cannot be made without a prostate biopsy. [-2]proPSA (p2PSA), a precursor of PSA, has been investigated as a new marker to accurately detect PCa. The aim of this systematic review was to discuss the available literature regarding the clinical validity and utility of p2PSA and its derivatives, p2PSA/fPSA (%p2PSA) and the Prostate Health Index (PHI). A systematic search of the PubMed and Scopus electronic databases was performed in accordance with the PRISMA statement (http://www.prisma-statement.org), considering the time period from January 1990 to January 2014 and using the following search terms: proprostate specific antigen, proenzyme PSA, proPSA, [-2]proPSA, p2PSA, Prostate Health Index, and PHI. To date, 115 studies have been published, but only 35 were considered for the qualitative analysis. These studies suggested that p2PSA is the most cancer-specific form of PSA, being preferentially expressed in PCa tissue and being significantly elevated in the serum of men with PCa. It is now evident that p2PSA, %p2PSA, and PHI measurements improve the specificity of the available tests (PSA and derivatives) in detecting PCa. Moreover, increasing PHI values seem to correlate with more aggressive disease. Some studies have compared p2PSA and its derivatives with other new biomarkers and found p2PSA to be significantly more accurate. Indeed, the implementation of these tests in clinical practice has the potential to significantly increase the physician's ability to detect PCa and avoid unnecessary biopsies, while also having an effective impact on costs. Further studies in large, multicenter, prospective trials are required to confirm these encouraging results on the clinical utility of these new biomarkers.
Humans
;
Male
;
Prostate-Specific Antigen/*blood
;
Prostatectomy
;
Prostatic Neoplasms/*diagnosis/pathology/surgery
;
Protein Isoforms/blood
;
Protein Precursors/*blood
;
Sensitivity and Specificity
;
Severity of Illness Index
;
Tumor Markers, Biological/blood
3.Current role of multiparametric magnetic resonance imaging in the management of prostate cancer.
Nikolas Christopher KATELARIS ; Damien Michael BOLTON ; Mahesha WEERAKOON ; Liam TONER ; Phillip Mark KATELARIS ; Nathan LAWRENTSCHUK
Korean Journal of Urology 2015;56(5):337-345
The purpose of this review was to evaluate the current role of multiparametric magnetic resonance imaging (mp-MRI) in the management of prostate cancer (PC). The diagnosis of PC remains controversial owing to overdetection of indolent disease, which leads to overtreatment and subsequent patient harm. mp-MRI has the potential to equilibrate the imbalance between detection and treatment. The limitation of the data for analysis with this new technology is problematic, however. This issue has been compounded by a paradigm shift in clinical practice aimed at utilizing this modality, which has been rolled out in an ad hoc fashion often with commercial motivation. Despite a growing body of literature, pertinent clinical questions remain. For example, can mp-MRI be calibrated to reliably detect biologically significant disease? As with any new technology, objective evaluation of the clinical applications of mp-MRI is essential. The focus of this review was on the evaluation of mp-MRI of the prostate with respect to clinical utility.
*Disease Management
;
Humans
;
Magnetic Resonance Imaging/*methods
;
Male
;
Prostate/*pathology
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Neoplasms/*diagnosis/pathology/surgery
4.Prostate cancer after prostatectomy for benign prostatic hyperplasia.
Lixin HUA ; Jiexiu ZHANG ; Hongfei WU ; Yuangeng SUI ; Wei ZHANG ; Lixin QIAN ; Zengjun WANG
National Journal of Andrology 2004;10(8):612-613
OBJECTIVETo study the diagnosis and treatment of prostate cancer after prostatectomy for benign prostatic hyperplasia (BPH).
METHODSTwelve cases of prostate cancer after prostatectomy for benign prostatic hyperplasia were reviewed and studied. The mean intervals between prostatectomy for BPH and the diagnosis of prostate cancer was 10 months to 14 years, 5.6 years on average. The main symptoms were dysuria, hematuria and pain. Serum prostate specific antigen (PSA) was elevated in 11 cases. Digital rectal examination (DRE) was abnormal in 8 cases. Three cases were in clinical stage B, 3 in stage C and 6 in stage D. Ten cases received combined androgen blockade therapy. Monotherapy with surgical castration was given to 2 cases. Three patients with urinary tract obstruction received additional treatment of TURP.
RESULTSDuring the 4 months to 8 years follow-up, 3 patients died, 6 remained stable and 2 deteriorated.
CONCLUSIONSurgery for BPH could not prevent the development of prostate cancer. PSA and DRE were the main methods for the diagnosis of this prostate cancer.
Aged ; Aged, 80 and over ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Postoperative Complications ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; surgery ; Prostatic Neoplasms ; diagnosis ; Retrospective Studies ; Transurethral Resection of Prostate
5.Biexponential Apparent Diffusion Coefficients Values in the Prostate: Comparison among Normal Tissue, Prostate Cancer, Benign Prostatic Hyperplasia and Prostatitis.
Xiaohang LIU ; Weijun PENG ; Liangping ZHOU ; He WANG
Korean Journal of Radiology 2013;14(2):222-232
OBJECTIVE: To investigate the biexponential apparent diffusion parameters of diverse prostate tissues and compare them with monoexponential apparent diffusion coefficient (ADC) value in the efficacy to discriminate prostate cancer from benign lesions. MATERIALS AND METHODS: Eleven healthy volunteers and 61 patients underwent a conventional (b-factors 0, 1000 s/mm2) and a 10 b-factor (0 to 3000 s/mm2) diffusion-weighted imaging (DWI). The monoexponential ADC value and biexponential parameters of fast ADC (ADCf), fraction of ADCf (f), slow ADC (ADCs) value for 29 prostate cancer, 28 benign prostatic hyperplasia (BPH), 24 prostatitis lesions and normal tissue were calculated and compared. Receiver operating characteristic analysis was performed to determine the sensitivity, specificity and optimal cut-off points. RESULTS: Prostate cancer had lower ADC, ADCf, f, and ADCs than all other tissues (p < 0.01). Prostatitis exhibited a lower ADC, ADCf, ADCs and f than the peripheral zone tissue (p < 0.01), and BPH showed a lower ADC and ADCf than the central gland tissue (p < 0.01). The ADCf demonstrated a comparable accuracy with ADC in differentiating cancer from BPH [area under the curve (AUC) 0.93 vs. 0.92] and prostatitis AUC 0.98 vs. 0.99) (both p > 0.05), but the AUC of f and ADCs in differentiating cancer from BPH (0.73 and 0.81) and prostatitis (0.88 and 0.91) were significantly lower than ADC (all p < 0.05). CONCLUSION: The biexponential DWI appears to provide additional parameters for tissue characterization in prostate, and ADCf helps to yield comparable accuracy with ADC in differentiating cancer from benign lesions.
Adult
;
Aged
;
Aged, 80 and over
;
Analysis of Variance
;
Biopsy
;
Diagnosis, Differential
;
*Diffusion Magnetic Resonance Imaging
;
Humans
;
Male
;
Middle Aged
;
Prospective Studies
;
Prostate-Specific Antigen/blood
;
Prostatectomy
;
Prostatic Hyperplasia/*diagnosis
;
Prostatic Neoplasms/*diagnosis/surgery
;
Prostatitis/*diagnosis
;
ROC Curve
;
Sensitivity and Specificity
6.Can We Predict Real T3 Stage Prostate Cancer in Patients with Clinical T3 (cT3) Disease before Radical Prostatectomy?.
Hye Won LEE ; Seong Il SEO ; Seong Soo JEON ; Hyun Moo LEE ; Han Yong CHOI
Yonsei Medical Journal 2010;51(5):700-707
PURPOSE: Down-staging of clinical T3 (cT3) prostate cancer after radical prostatectomy (RP) is not uncommon due to the inaccuracy of the currently available staging modalities, although selected down-staged cT3 patients can be a candidate for definitive RP. We identified the significant predictors for down-staging of cT3 after RP. MATERIALS AND METHODS: We included 67 patients with cT3 stage prostate cancer treated with radical perineal prostatectomy (RPP) between 1998 and 2006 and reviewed their medical records retrospectively. The clinical stage was obtained according to the DRE, the prostate biopsy findings, and the prostate MRI. RESULTS: Fifty three (79%) patients with cT3 prostate cancer were down-staged to pT2 after RP. The percent of positive cores had the strongest association with down-staging of cT3 [p = 0.01, odds ratio (OR) = 6.3], followed by baseline prostate specific antigen (PSA) (p = 0.03, OR = 5.0), the biopsy Gleason sum (GS) (p = 0.03, OR = 4.7), and the maximum tumor volume of the positive cores (p = 0.05, OR = 4.0). When the cut-off points of significant parameters which were a PSA < 10 ng/mL, a percent of positive cores < or = 30%, a maximum tumor volume of the positive cores < or = 75% and GS < or = 7 were combined, the sensitivity, specificity, and positive predictive value were 0.25%, 1.00%, and 100%, respectively. CONCLUSION: The percent of positive cores < or = 30%, serum PSA < 10 ng/mL, the biopsy GS < or = 7, and the maximum tumor volume of the positive cores < or = 75% were the significant predictors of down-staging cT3 disease after RP.
Aged
;
Humans
;
Magnetic Resonance Imaging
;
Male
;
Middle Aged
;
Neoplasm Staging
;
Predictive Value of Tests
;
Prostate-Specific Antigen/blood
;
*Prostatectomy
;
Prostatic Neoplasms/blood/diagnosis/*pathology/*surgery
7.The focus and prospect of prostate cancer research.
Hanzhong LI ; Email: LIHANZHONG@MEDMAIL.COM.CN. ; Dexin DONG
Chinese Journal of Surgery 2015;53(4):253-256
The incidence and mortality of prostate cancer in China are increasing year by year. The review is focused on current hot prospects of prostate cancer. The value of serum prostate specific antigen (PSA) screening is still controversial, and PSA screening in high-risk groups is recommended for early diagnosis of prostate cancer. Prostate biopsy including transrectal approach and perineal approach, and two methods have both advantages and disadvantages. There is significant correlation between testosterone levels and the prognosis of prostate cancer, and the monitoring of testosterone level contributes to the treatment. The main complications of radical resection of prostate cancer is urinary incontinence and erectile dysfunction, three-dimensional laparoscopic and robot assisted laparoscopic techniques have obvious advantages in radical operation. Brachytherapy is another option for radical treatment, with relaxed age limit, low incidence of erectile dysfunction, urinary incontinence and reliable curative effect. The diagnosis and treatment of new technologies include such as MRI dynamic enhancement scan, ¹⁸F-fluoroethyl PET/CT, ultrasound contrast technology, prostate cancer immunotherapy, et al.
Biopsy
;
Brachytherapy
;
China
;
Early Detection of Cancer
;
Humans
;
Laparoscopy
;
Male
;
Prognosis
;
Prostate-Specific Antigen
;
blood
;
Prostatic Neoplasms
;
diagnosis
;
radiotherapy
;
surgery
;
Robotic Surgical Procedures
;
Testosterone
;
blood
;
Urinary Incontinence
8.Clinical outcomes of laparoscopic radical prostatectomy for high risk prostate cancer.
Pengfei SHAO ; Changjun YIN ; Email: CHANGJUNYIN@HOTMAIL.COM. ; Jie LI ; Pu LI ; Xiaobing JU ; Qiang LYU ; Xiaoxin MENG ; Lixin HUA
Chinese Journal of Surgery 2015;53(11):847-851
OBJECTIVETo study the technique and clinical outcomes of laparoscopic radical prostatectomy for high risk prostate cancer.
METHODSA total of 65 patients with high risk prostate cancer were treated with surgery in the First Affiliated Hospital of Nanjing Medical University from January 2011 to June 2013. The mean age was 67 years (range 45-75 years). The mean preoperative prostate specific antigen (PSA) level was 26.7 µg/L (range 11.2-65.5 µg/L). The transrectal biopsy revealed Gleason score of 3+3 in 4 patients, Gleason 3+4 in 27 patients, Gleason 4+3 in 11 patients, Gleason 4+4 in 21 patients and Gleason 4+5 in 2 patients. The bone metastasis was excluded by scintigraphy examination. The surgical procedures were performed through transperitoneal approach. Extended pelvic lymph nodes dissection was performed after the removal of the prostate. Adjuvant radiotherapy or hormonal therapy was administrated according to the pathological results. Serum PSA was detected every 1 to 2 month and urinary continence was evaluated every 3 month in the first year, and then serum PSA was detected every 2 to 3 month.
RESULTSThe mean operative time was (134±21) minutes and the median blood loss was (300±146) ml. Bladder neck reconstruction was performed in 15 cases. The drainage was removed on postoperative day 4 and the catheter was removed on day 7. Pathologic results demonstrated pT2 in 25 patients, pT3a in 28 patients, pT3b in 9 patients and pT4 in 3 patients. Positive surgical margin was presented in 15 patients. A median of 19 lymph nodes (range 11-24 nodes) were retrieved during lymphadenectomy and 11 patients had lymph nodes metastasis with a total of 19 positive nodes. Forty-three patients recovered continence after the removal of catheter. Eleven patients received adjuvant hormonal therapy and 19 patients received adjuvant radiation therapy. With the median of 20 months follow-up (range 12-30 months), 5 patients got biochemical recurrence.
CONCLUSIONSLaparoscopic radical prostatectomy with extended lymph nodes dissection for high risk prostate cancer is safe and technical feasible. It provides accurate information on tumor stage and grade. It is an important component of multimodality for the treatment of high risk prostate cancer.
Aged ; Biopsy ; Humans ; Laparoscopy ; Lymph Node Excision ; Lymph Nodes ; pathology ; Lymphatic Metastasis ; Male ; Middle Aged ; Neoplasm Grading ; Postoperative Period ; Prostate-Specific Antigen ; blood ; Prostatectomy ; Prostatic Neoplasms ; diagnosis ; surgery
9.Influence of clinical factors on Gleason score upgrade in patients undergoing radical prostatectomy.
Guiming ZHANG ; Xiaojian QIN ; Chengtao HAN ; Chengyuan GU ; Fangning WAN ; Yuanyuan QU ; Weijie GU ; Chunguang MA ; Yao ZHU ; Dingwei YE ; Email: DWYELI@163.COM.
Chinese Journal of Surgery 2015;53(7):543-546
OBJECTIVETo evaluate clinical factors affecting Gleason score upgrade in patients receiving radical prostatectomy (RP).
METHODSA total of 322 patients with prostate cancer who received RP from January 2012 to December 2013 at Department of Urology at Fudan University Shanghai Cancer Center were included, and their data of age, body mass index (BMI), prostate-specific antigen (PSA), prostate volume, percentage core, clinical staging, pathological characteristics, biopsy Gleason score and RP Gleason score were analyzed. Differences in categorical variables and continuous variables were compared using χ² tests and Student's t-test, respectively. Unconditional multiple logistic regression was used to estimate OR and 95% CI of the association of Gleason score upgrade with clinical factors.
RESULTSGleason score upgrade occurred in 107 of 322 (33.3%) patients. There was no difference in age, BMI and clinical staging between the two groups. Compared with patients without Gleason score upgrade, higher levels of PSA (χ² =6.740, P=0.034), smaller prostate volume (t=3.481, P=0.002) and elevated percentage core (t=-2.097, P=0.037) were observed in patients with Gleason score upgrade. In addition, lymph node metastasis (χ² =4.193, P=0.041) and extracapsular extension (χ² =4.747, P=0.029) were more common in patients with Gleason score upgrade. After adjusting for potential confounders, PSA levels (OR=2.451, 95% CI: 1.290-4.660), prostate volume (OR=0.982, 95% CI: 0.969-0.995) and percentage core (OR=2.756, 95% CI: 1.033-7.357) were independent predictors for Gleason score upgrade.
CONCLUSIONGleason score upgrade happens at a relatively high rate. PSA levels, prostate volume and percentage core are important factors affecting Gleason score upgrade.
Biopsy ; Body Mass Index ; China ; Humans ; Logistic Models ; Male ; Multivariate Analysis ; Neoplasm Grading ; Prostate-Specific Antigen ; blood ; Prostatectomy ; Prostatic Neoplasms ; diagnosis ; surgery
10.Diagnostic Role of Prostate Resection in the Elderly Patients Who Experience Significant Co-Morbidity with a High Clinical Suspicion of Prostate Cancer.
Ho Won KANG ; Jin Bak YANG ; Whi An KWON ; Young Suk LEE ; Won Tae KIM ; Yong June KIM ; Seok Joong YUN ; Sang Cheol LEE ; Isaac Yi KIM ; Wun Jae KIM
Journal of Korean Medical Science 2013;28(12):1796-1800
The necessity of routine prostate biopsy prior to transurethral resection of the prostate (TURP) in elderly comorbid patients with a high prostate specific antigen (PSA) level remains controversial. We assessed the role of TURP in prostate cancer diagnosis in these individuals. A total of 197 patients underwent TURP in conjunction with prostatic needle biopsy. Pathologic reviews of specimens of TUR chips and biopsy cores were analyzed. Overall, prostate cancer (CaP) was detected in 114 patients (57.6%). Ninety-eight cancers (86%) were detected with TURP and biopsy, and seven cancers (6.1%) with only TURP. The Gleason score of a TUR-specimen was identical to that of the biopsy-core in 43.9% of cases. Variables associated with diagnostic accuracy in the TUR-specimens included the prebiopsy PSA level, prostate specific antigen density (PSAD), and the Gleason score in biopsy cores. In patients with a PSA level and a PSAD that was greater than 15.4 ng/mL and 0.69 ng/mL/g, respectively, 100% of the cancers were detected in the TUR-specimens. Our results suggest that a prostatic biopsy might be omitted prior to TURP in elderly patients with significant co-morbidity and levels for PSA of >15.4 ng/mL.
Aged
;
Aged, 80 and over
;
Area Under Curve
;
Biopsy, Needle
;
Comorbidity
;
Humans
;
Male
;
Neoplasm Grading
;
Prostate/*surgery
;
Prostate-Specific Antigen/*blood
;
Prostatic Neoplasms/*diagnosis/epidemiology/*pathology/surgery
;
ROC Curve
;
Transurethral Resection of Prostate